Researchers have developed SCOPE-AD, a new method for diagnosing Alzheimer's disease that considers the cost and patient burden of sequential evidence acquisition.
On ADNI, SCOPE-AD achieves 77.70\% Macro-F1 at an average acquisition cost of \$50.46, exceeding the strongest evaluated baseline by 9.34 percentage points.
On ADNI, SCOPE-AD achieves 77.70\% Macro-F1 at an average acquisition cost of \$50.46
Abstract: Alzheimer's disease (AD) diagnosis requires sequential evidence acquisition under heterogeneous test costs and patient burden. Fixed-modality predictors do not jointly decide which test to acquire or when the available evidence is sufficient for diagnosis. We propose SCOPE-AD (Sequential Cost-Aware Ordinal-Belief Planning with Energy-Based Models for Diagnostic Agents) for cost-aware cl…
